Open AccessSustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers
Author(s) -
Hao Li,
Wenzhong Liu,
Christine M. Sorenson,
Nader Sheibani,
Daniel M. Albert,
Thulani H. Senanayake,
Serguei V. Vinogradov,
Jack Henkin,
Hao F. Zhang
Publication year - 2017
Publication title -
investigative ophthalmology and visual science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.17-22160
Subject(s) - nanocarriers , peptide , chemistry , arginine , biochemistry , organic chemistry , drug delivery , amino acid
Intravitreal injection of antiangiogenic agents is becoming a standard treatment for neovascular retinal diseases. Sustained release of therapeutics by injecting colloidal carriers is a promising approach to reduce the injection frequency, which reduces treatment burdens and the risk of complications on patients. Such sustained release often requires carriers to have micrometer-scale dimension that, however, can potentially promote glaucoma and inflammation. Small, polycationic particles can be immobilized in vitreous through multiple cooperative ionic interactions with hyaluronic acid of the vitreous interior, but such particles are generally toxic. Here, we synthesized and examined a biocompatible dextran-based nanocarrier (<50 nm in diameter) conjugated with cationic peptides containing L-arginine with minimal toxicity, aiming to provide sustained release of therapeutic drugs in vitreous.